Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;62(6):1474-1481.
doi: 10.1080/10428194.2020.1869962. Epub 2021 Jan 8.

The association between non-steroidal anti-inflammatory drugs (NSAIDs) and myelodysplastic syndromes in the Adults in Minnesota with Myelodysplastic Syndromes (AIMMS) Study

Affiliations

The association between non-steroidal anti-inflammatory drugs (NSAIDs) and myelodysplastic syndromes in the Adults in Minnesota with Myelodysplastic Syndromes (AIMMS) Study

Aubrey K Hubbard et al. Leuk Lymphoma. 2021 Jun.

Abstract

Myelodysplastic syndromes (MDS) are a heterogeneous group of blood disorders. Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with a chemopreventive effect in some cancers. We evaluated associations between NSAID use and MDS in a population-based case-control study. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Secondary analyses stratified by sex and MDS subtype were also conducted.The analysis included 399 MDS cases and 698 controls. No significant associations between MDS and use of aspirin (OR = 0.87, 95% CI 0.67-1.14), ibuprofen (OR = 0.91, 95% CI 0.64-1.30), acetaminophen (OR = 1.29, 95% CI 0.90-1.84) or NSAIDs overall (OR = 0.92, 95% CI 0.68-1.23) were observed. No significant associations were observed in models stratified by sex or MDS subtype; however, the direction of the effect between NSAID use and MDS varied by MDS subtype. Our results do not support an association between NSAID use and MDS overall.

Keywords: Myelodysplastic syndromes; epidemiology; non-steroidal anti-inflammatory drug.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors have no financial conflicts of interest to disclose.

Similar articles

Cited by

References

    1. Catenacci DVT, Schiller GJ. Myelodysplasic syndromes: A comprehensive review. Blood Rev. 2005;19(6):301–319. doi:10.1016/j.blre.2005.01.004 - DOI - PubMed
    1. Tefferi A, Vardiman JW. Myelodysplastic Syndromes. N Engl J Med. 2009;361(19):1872–1885. doi:10.1056/NEJMra0902908 - DOI - PubMed
    1. Disperati P, Ichim CV., Tkachuk D, Chun K, Schuh AC, Wells RA. Progression of myelodysplasia to acute lymphoblastic leukaemia: Implications for disease biology. Leuk Res. 2006;30(2):233–239. doi:10.1016/J.LEUKRES.2005.06.011 - DOI - PubMed
    1. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes. Cancer. 2007;109(8):1536–1542. doi:10.1002/cncr.22570 - DOI - PubMed
    1. Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 2011;9(1):30–56. doi:10.6004/JNCCN.2011.0005 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances